Want to see MOVE full AI Analyst Report?
Top Page
Corvex
(NASDAQ:MOVE)
Select Model
Select Model
Rating:43Neutral
Price Target:
$8.50
▼(-23.84% Downside)
Action:Reiterated
Date:10/15/26
The score is held down primarily by weak fundamentals (large losses and continued negative free cash flow) despite improved revenue scale and a low-leverage balance sheet. Technicals also remain bearish with price below major moving averages and negative MACD. Valuation is constrained by negative earnings, and the new ATM financing improves flexibility but raises dilution concerns.
Positive Factors
Revenue scale-up
The sharp increase in trailing-twelve-month revenue indicates meaningful progress in commercialization and market activity. If this higher sales scale persists, it can improve operating leverage, support product investment, and provide a stronger base for developing a sustainable business model.
Negative Factors
Persistent unprofitability
Negative gross profit and substantial losses show that current revenue is not yet covering the economics of the business. Until margins improve materially, Corvex may need continued external funding and could face difficulty converting commercialization progress into durable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue scale-up
The sharp increase in trailing-twelve-month revenue indicates meaningful progress in commercialization and market activity. If this higher sales scale persists, it can improve operating leverage, support product investment, and provide a stronger base for developing a sustainable business model.
Read all positive factors
Corvex (MOVE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$269.46M
Dividend YieldN/A
Average Volume (3M)154.22K
Price to Earnings (P/E)―
Beta (1Y)1.96
Revenue Growth843.62%
EPS Growth21.98%
CountryUS
Employees38
SectorTechnology
Sector Strength88
IndustrySoftware - Infrastructure
Share Statistics
EPS (TTM)-12.24
Shares Outstanding31,552,275
10 Day Avg. Volume70,948
30 Day Avg. Volume154,220
Financial Highlights & Ratios
PEG Ratio1.00
Price to Book (P/B)-201.10
Price to Sales (P/S)1613.48
P/FCF Ratio-62.00
Enterprise Value/Market Cap2.32
Enterprise Value/Revenue140.88
Enterprise Value/Gross Profit-210.94
Enterprise Value/Ebitda-27.10
Forecast
1Y Price Target
$18.75Price Target Upside68.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-10.68
Revenue Forecast (FY)$30.50M
Corvex Business Overview & Revenue Model
Company Description
Corvex, Inc., an AI cloud computing company, provides GPU-accelerated infrastructure for AI workloads to customers worldwide. The company provides graphics processing unit accelerated compute, confidential computing, token factory, and inference s...
How the Company Makes Money
Movano’s monetization is expected to come primarily from commercializing its device-and-software ecosystem. Potential revenue streams include: (1) sales of wearable hardware devices (one-time revenue per unit sold); (2) recurring software and serv...
Corvex Earnings Call Summary
Earnings Call Date:Nov 14, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:May 25, 2027
Earnings Call Sentiment Positive
The earnings call highlighted several achievements, including successful sales of the Evie Rings, progress towards FDA clearance, and positive customer feedback. However, challenges such as stock price issues and financial concerns were also discussed. Overall, the sentiment leans slightly positive due to the company's forward momentum and strategic planning.Positive Updates
Successful Sale of Evie Rings
Movano Health reported ongoing successful sales and fulfillment of Evie Rings following a back in-stock announcement on September 17.
Negative Updates
Stock Price and Reverse Split Issues
Movano implemented a 1-for-15 reverse stock split to regain compliance with NASDAQ listing requirements, and is investigating potential stock manipulation during the process.
Read all updates
Q3-2024 Updates
Positive
Negative
Successful Sale of Evie Rings
Movano Health reported ongoing successful sales and fulfillment of Evie Rings following a back in-stock announcement on September 17.
Read all positive updates
Company Guidance
During the Movano Health Q3 2024 earnings call, the company provided guidance on several key metrics and strategic initiatives. Movano Health is optimistic about both its direct-to-consumer (D2C) and business-to-business (B2B) opportunities, emphasizing the EvieMed ring's anticipated FDA 510(k) clearance. The company has successfully shipped 339 Evie rings since resuming sales in September, achieving a 90%+ customer service approval score. It plans to capitalize on the upcoming Black Friday/Cyber Monday sales period with an entirely organic marketing strategy, resulting in efficient customer acquisition costs. Financially, Movano reported a Q3 operating loss of $7.4 million, down from $9.1 million in the previous year, with a cash position of $11.3 million as of September 30, 2024. The company continues to manage its cash burn carefully, which was approximately $5.6 million for the quarter. Additionally, Movano is exploring commercial opportunities with major pharmaceutical and healthcare partners, preparing for a pilot program in Q1 2025, and advancing its blood pressure and glucose monitoring technologies.Corvex Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.43M | 433.00K | 1.01M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.96M | -1.84M | -1.99M | -158.00K | -134.00K | 0.00 |
| EBITDA | -23.05M | -15.17M | -23.56M | -29.13M | -30.18M | -20.82M |
| Net Income | -27.65M | -18.29M | -23.73M | -29.28M | -30.20M | -22.58M |
Balance Sheet | ||||||
| Total Assets | 599.32M | 5.60M | 11.32M | 9.42M | 13.24M | 36.27M |
| Cash, Cash Equivalents and Short-Term Investments | 21.70M | 2.83M | 7.90M | 6.12M | 10.76M | 33.60M |
| Total Debt | 14.96M | 4.90M | 186.00K | 217.00K | 426.00K | 0.00 |
| Total Liabilities | 26.07M | 9.07M | 3.96M | 5.97M | 5.33M | 3.54M |
| Stockholders Equity | 573.25M | -3.47M | 7.36M | 3.45M | 7.92M | 32.73M |
Cash Flow | ||||||
| Free Cash Flow | -19.91M | -11.27M | -22.54M | -26.24M | -25.01M | -16.75M |
| Operating Cash Flow | -13.43M | -11.27M | -22.53M | -26.18M | -24.90M | -16.18M |
| Investing Cash Flow | 29.79M | 0.00 | -8.00K | -64.00K | 15.72M | -16.70M |
| Financing Cash Flow | 3.23M | 6.19M | 24.32M | 21.60M | 2.26M | 44.85M |
Corvex Technical Analysis
Negative
11.16
Price Trends
10.75
Negative
13.58
Negative
12.95
Negative
Market Momentum
-0.90
Positive
31.99
Neutral
39.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MOVE, the sentiment is Negative. The current price of 11.16 is above the 20-day moving average (MA) of 9.93, above the 50-day MA of 10.75, and below the 200-day MA of 12.95, indicating a bearish trend. The MACD of -0.90 indicates Positive momentum. The RSI at 31.99 is Neutral, neither overbought nor oversold. The STOCH value of 39.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MOVE.
Corvex Risk Analysis
Corvex disclosed 89 risk factors in its most recent earnings report. Corvex reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Corvex Peers Comparison
UnderperformOutperform
Sector (61)
MOVE
Corvex
8.07
3.09
62.15%
BBLG
Bone Biologics
0.41
-1.81
-81.67%
BJDX
Bluejay Diagnostics
0.63
-9.09
-93.54%
AMIX
Autonomix Medical, Inc.
2.50
-21.02
-89.37%
Corvex Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Corvex Launches ATM Equity Program With Chardan Capital
Positive
Oct 14, 2026
On October 14, 2026, Corvex, Inc. entered into an at-the-market sales agreement with Chardan Capital Markets LLC, appointing the firm as sales agent, and in certain periods as exclusive agent, to place shares of Corvex’s common stock under a...
Financial DisclosuresM&A TransactionsStock Split
Corvex finalizes Movano merger and equity restructuring
Neutral
Sep 4, 2026
On March 19, 2026, Corvex, Inc., formerly Movano Inc., completed its merger with Corvex Legacy Holdings, Inc., making Corvex OpCo a wholly owned subsidiary and later adopting the Corvex name on March 23, 2026. The consideration, structured through...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.